$REPL News

Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Replimune Group Says FDA Accepts Resubmission Of BLA For RP1 In Combination With Nivolumab For Advanced Melanoma, With August 2 Goal Date And Expects Adcom Meeting In Late July

Replimune: Modeling The Coin Flip Of FDA Approval

Why Is REPL Stock Gaining In Pre-Market Today?

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPL Stock Shot Up 80% Today – What’s The Deal With FDA?

Market Chatter: Replimune Plans to Resubmit Melanoma Therapy Application for FDA Approval

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

'Replimune Gets Third Try at FDA Approval After Makary Departure' - Wall Street Journal

Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1

Live On CNBC, FDA's Makary Defends Agency's Decision On Replimune's Cancer Drug; Says Three Indepndent Teams Arrived At The Same Conclusions

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision

Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns

FDA Rejection Sparks Questions On Replimune Drug Approval Path

Cantor Fitzgerald Downgrades Replimune Group to Neutral